Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Shen Lian Biomedical Days Payable?
Shanghai Shen Lian BiomedicalSHSE:688098 +2.31%69 Days Payable is 72.93 as of Mar. 2026, which is 118% above its 10-year median of 33.40. GuruFocus rates SHSE:688098 with a GF Score™ of 69/100 and a GF Value™ of ¥5.86 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Shanghai Shen Lian Biomedical ranks worse than 73.5% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688098 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Shanghai Shen Lian Biomedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shen Lian Biomedical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Shen Lian Biomedical's Days Payable distribution charts can be found below:
* The bar in red indicates where Shanghai Shen Lian Biomedical's Days Payable falls into.
Shanghai Shen Lian Biomedical Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shen Lian Biomedical (SHSE:688098) has a Days Payable of 72.93 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Shen Lian Biomedical and its competitors. This is 118% above median its historical median of 33.40. Over the past decade, Shanghai Shen Lian Biomedical's Days Payable has ranged from 16.01 to 49.13. According to the industry distribution chart, Shanghai Shen Lian Biomedical ranks #516 out of 702 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Shanghai Shen Lian Biomedical's Days Payable too high?
Shanghai Shen Lian Biomedical's current Days Payable of 72.93 is 118% above median its 10-year median of 33.40. Over the past 10 years, this metric has ranged from a low of 16.01 to a high of 49.13. The Biotechnology industry median Days Payable is 113.10. Shanghai Shen Lian Biomedical's value of 72.93 is 35.5% below this industry median. Based on the distribution chart, Shanghai Shen Lian Biomedical ranks #516 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Shen Lian Biomedical has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shen Lian Biomedical's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Shen Lian Biomedical ranks #516 out of 702 companies for Days Payable. This places Shanghai Shen Lian Biomedical in the lower half of its industry. The industry median Days Payable is 113.10. Shanghai Shen Lian Biomedical's value of 72.93 is 35.5% below this benchmark. Historically, Shanghai Shen Lian Biomedical's own Days Payable has ranged from 16.01 to 49.13 over the past decade. While the company's 10-year median is 33.40 vs. the industry median of 113.10, Shanghai Shen Lian Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shen Lian Biomedical's current Days Payable of 72.93 is 35.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Shen Lian Biomedical and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shen Lian Biomedical's current Days Payable is 72.93, which is 118% above median its own 10-year median of 33.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shen Lian Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical (SHSE:688098) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.86, compared to a current price of ¥8.40 — trading 43.3% above its estimated fair value. The current Days Payable is 72.93, which is 118% above median its 10-year median of 33.40 and 35.5% below the Biotechnology industry median of 113.10. Shanghai Shen Lian Biomedical's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai Shen Lian Biomedical (SHSE:688098), the current Days Payable is 72.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shen Lian Biomedical (SHSE:688098) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical stock appears to be overvalued.
The current stock price of ¥8.40 is trading 43.3% above its estimated GF Value™ of ¥5.86.
GuruFocus considers Shanghai Shen Lian Biomedical to be Significantly Overvalued.
Key valuation signals for SHSE:688098:
Days Payable: 72.93 (118% above median its 10-year median of 33.40)
GF Value™: ¥5.86 vs. price of ¥8.40 (43.3% above fair value)
Industry Position: 35.5% below the Biotechnology median (#516 of 702)
No single metric tells the full story. See the SHSE:688098 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shen Lian Biomedical Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688098 has been successfully added to your 
